Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SKYS +65.8%, (thinly traded), OSUR +23.4%, AVNW +15.9%, (thinly traded), TZOO +11.6%, PAYC +11%,ZEN +10.1%, MPAA +9.8%, CLF +9.8%, PCMI +9.5%
- IMPV +9.3%, (also agrees to sell its Skyfence technology and service to Forcepoint, financial details not disclosed; acquires the assets of Camouflage Software)
- WSTL +8.4%, FLT +7.8%, PRLB +6.5%, SCSS +6.2%, MDSO +6.1%, LLNW +5.4%, CXW +5.2%, LIVE +4.4%, ARRY +3.5%, ALNY +3.4%, RLGT +3.4%
- VIA +3%, CMP +2.9%, FONR +2.7%, AOSL +2.5%, GPRE +2.2%, CVS +2.2%, MFC +2%, EFX +1.9%, TU +1.9%, CETX +1.9%, FORM +1.6%, CMI +1.6%
- PTN +1.4%, WWE +1.4%, BGCP +1.3%, ROP +1.2%, RAI +1.1%, PSEC +1%, TOT +1%, RMR +0.9%,OHI +0.8%, CRAY +0.8%, AFG +0.7%, YUM +0.6%, PRU +0.5%
M&A news:
- JAGX +69% (Jaguar Animal Health to merge with Napo Pharmaceuticals)
- NOK +1.4% (to acquire Comptel for EUR 347 mln)
Other news:
- ETRM +17.8% (publication of three-year data from the Company's VBLOC DM2 Study of vBloc Neurometabolic Therapy)
- AQMS +16.1% (announces that Johnson Controls (JCI) finalized an agreement covering North America, China and Europe for its technology)
- RELV +14.7% (thinly traded; announced that CardioSentials heart health supplement has earned a U.S. patent)
- ACOR +12.3% (announces 'positive' Phase 3 data of CVT-301 'showing a statistically significant improvement in motor function in people with Parkinson's disease experiencing OFF periods)
- VKTX +11.7% (announces 'positive' initial results from a proof-of-concept study of VK2809)
- PPHM +9.9% (announces the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform)
- BANC +5.6% (Banc of California appoints Richard Lashley, co-founder of 6.9% holder PL Capital Advisors, to the Board and approves certain enhancements to corporate governance policies)
- URRE +3.8% (announces its Special meeting not convened, nor adjourned to later date; RCF debt to be repaid from treasury)
- STB +3.2% ( awarded new record $187 million contract )
- SNY +2.3% (Regeneron Pharma confirms appeals court grants stay of permanent injunction for Praluent (alirocumab) during appeals process)
- TSLA +2.1% (Reuters details that Tesla (TSLA) plans to pause factory production in California to prepare for Model 3)
- XGTI +2.1% (prices offering of 1.75 mln shares of common stocks and warrants of up to 1.3 mln shares at $2.00 per share)
- ETP +1.7% (received US Army Corps of Engineers easement to construct N Dakota pipeline (as expected - see Feb 7 comments); Dakota Access has now received all federal authorizations necessary to proceed)
- BP +1.1% (in sympathy with TOT earnings)
- RDS.A +1.1% (in sympathy with TOT earnings)
- DECK +0.9% (following late move higher on Marcato active stake disclosure)
- BA +0.8% (confirms that Singapore Airlines has commited to purchase 20 777-9s and 19 787-10 Dreamliners)
Analyst comments:
- RMBS +2.8% (upgraded to Overweight from Neutral at JP Morgan)
- FNV +0.7% (upgraded to Neutral from Sell at Goldman)
- ALV +0.6% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts)